STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial

Phase 1positiveorexin agonistPositive

AI Analysis

Summary

Alkermes announced that its orexin agonist demonstrated potential for treating ADHD in an early-stage clinical trial, marking the first evidence of this therapeutic approach in this indication.

Clinical Trial Data

Phase

Outcome Details

Orexin agonist showed potential to treat ADHD in early-stage study

Importance:5/10

Sentiment:

0.60

ADHDorexin agonistearly-stage trialneurology

Related Companies

$TRAX

Read the original article

Published by STAT News on September 21, 2026 11:00 AM

Read Original